594 related articles for article (PubMed ID: 8555653)
1. Combined effects of buthionine sulfoximine and cepharanthine on cytotoxic activity of doxorubicin to multidrug-resistant cells.
Kisara S; Furusawa S; Murata R; Ogata M; Hikichi N; Takayanagi Y; Sasaki K
Oncol Res; 1995; 7(3-4):191-200. PubMed ID: 8555653
[TBL] [Abstract][Full Text] [Related]
2. d,l-buthionine-(S,R)-sulfoximine potentiates in vivo the therapeutic efficacy of doxorubicin against multidrug resistance protein-expressing tumors.
Vanhoefer U; Cao S; Minderman H; Toth K; Skenderis BS; Slovak ML; Rustum YM
Clin Cancer Res; 1996 Dec; 2(12):1961-8. PubMed ID: 9816155
[TBL] [Abstract][Full Text] [Related]
3. Effect of buthionine sulfoximine and ethacrynic acid on cytotoxic activity of mitomycin C analogues BMY 25282 and BMY 25067.
Xu BH; Singh SV
Cancer Res; 1992 Dec; 52(23):6666-70. PubMed ID: 1423311
[TBL] [Abstract][Full Text] [Related]
4. Combination of cyclosporin A and buthionine sulfoximine (BSO) as a pharmacological strategy for circumvention of multidrug resistance in small cell lung cancer cell lines selected for resistance to doxorubicin.
Larsson R; Bergh J; Nygren P
Anticancer Res; 1991; 11(1):455-9. PubMed ID: 1850223
[TBL] [Abstract][Full Text] [Related]
5. Reversal of doxorubicin resistance in multidrug resistant melanoma cells in vitro and in vivo by dipyridamole.
Desai PB; Duan J; Sridhar R; Damle BD
Methods Find Exp Clin Pharmacol; 1997 May; 19(4):231-9. PubMed ID: 9228648
[TBL] [Abstract][Full Text] [Related]
6. Potentiation of doxorubicin cytotoxicity by buthionine sulfoximine in multidrug-resistant human breast tumor cells.
Dusre L; Mimnaugh EG; Myers CE; Sinha BK
Cancer Res; 1989 Feb; 49(3):511-5. PubMed ID: 2535960
[TBL] [Abstract][Full Text] [Related]
7. Effect of glutathione depletion by buthionine sulfoximine on doxorubicin toxicity in mice.
Kisara S; Furusawa S; Takayanagi Y; Sasaki K
Res Commun Mol Pathol Pharmacol; 1995 Sep; 89(3):401-10. PubMed ID: 8680808
[TBL] [Abstract][Full Text] [Related]
8. Chemosensitization of L-phenylalanine mustard by the thiol-modulating agent buthionine sulfoximine.
Kramer RA; Greene K; Ahmad S; Vistica DT
Cancer Res; 1987 Mar; 47(6):1593-7. PubMed ID: 3815359
[TBL] [Abstract][Full Text] [Related]
9. Mitomycin C sensitivity in human bladder cancer cells: possible role of glutathione and glutathione transferase in resistance.
Xu BH; Gupta V; Singh SV
Arch Biochem Biophys; 1994 Jan; 308(1):164-70. PubMed ID: 8311448
[TBL] [Abstract][Full Text] [Related]
10. Overexpression of glutathione S-transferase and elevation of thiol pools in a multidrug-resistant human colon cancer cell line.
Chao CC; Huang YT; Ma CM; Chou WY; Lin-Chao S
Mol Pharmacol; 1992 Jan; 41(1):69-75. PubMed ID: 1346333
[TBL] [Abstract][Full Text] [Related]
11. Inhibition of buthionine sulfoximine-enhanced doxorubicin toxicity in metallothionein overexpressing transgenic mouse heart.
Wu HY; Kang YJ
J Pharmacol Exp Ther; 1998 Nov; 287(2):515-20. PubMed ID: 9808675
[TBL] [Abstract][Full Text] [Related]
12. Buthionine sulfoximine enhances glutathione-but attenuates glutamate-stimulated cell proliferation.
Kang YJ
Cell Mol Biol Res; 1995; 41(2):131-6. PubMed ID: 8581064
[TBL] [Abstract][Full Text] [Related]
13. Lack of enhanced antitumor efficacy for L-buthionine sulfoximine in combination with carmustine, cyclophosphamide, doxorubicin or melphalan in mice.
Soble MJ; Dorr RT
Anticancer Res; 1988; 8(1):17-22. PubMed ID: 3358633
[TBL] [Abstract][Full Text] [Related]
14. Effect of buthionine sulfoximine on toxicity of verapamil and doxorubicin to multidrug resistant cells and to mice.
Ford JM; Yang JM; Hait WN
Cancer Res; 1991 Jan; 51(1):67-72. PubMed ID: 1988108
[TBL] [Abstract][Full Text] [Related]
15. Reduction of doxorubicin resistance by tetrandrine and dauricine in harringtonine-resistant human leukemia (HL60) cells.
He QY; Meng FH; Zhang HQ
Zhongguo Yao Li Xue Bao; 1996 Mar; 17(2):179-81. PubMed ID: 9772674
[TBL] [Abstract][Full Text] [Related]
16. Complete reversal by thaliblastine of 490-fold adriamycin resistance in multidrug-resistant (MDR) human breast cancer cells. Evidence that multiple biochemical changes in MDR cells need not correspond to multiple functional determinants for drug resistance.
Chen G; Waxman DJ
J Pharmacol Exp Ther; 1995 Sep; 274(3):1271-7. PubMed ID: 7562498
[TBL] [Abstract][Full Text] [Related]
17. Reversal effect of isotetrandrine, an isoquinoline alkaloid extracted from Caulis Mahoniae, on P-glycoprotein-mediated doxorubicin-resistance in human breast cancer (MCF-7/DOX) cells.
Wang TX; Yang XH
Yao Xue Xue Bao; 2008 May; 43(5):461-6. PubMed ID: 18717331
[TBL] [Abstract][Full Text] [Related]
18. Effect of doxorubicin on glutathione and glutathione-dependent enzymes in cultured rat heart cells.
Paranka NS; Dorr RT
Anticancer Res; 1994; 14(5A):2047-52. PubMed ID: 7847848
[TBL] [Abstract][Full Text] [Related]
19. The role of a novel copper complex in overcoming doxorubicin resistance in Ehrlich ascites carcinoma cells in vivo.
Majumder S; Dutta P; Mookerjee A; Choudhuri SK
Chem Biol Interact; 2006 Feb; 159(2):90-103. PubMed ID: 16289015
[TBL] [Abstract][Full Text] [Related]
20. The ability of selected pyridinium salts to increase the cytotoxic activity of vincristine but not doxorubicin towards sensitive and multidrug resistant promyelocytic leukaemia HL60 cells.
Maruszewska A; Kostrzewa-Nowak D; Adamus J; Czupryńska K; Maryniak D; Gebicki J; Tarasiuk J
J Pharm Pharmacol; 2008 May; 60(5):647-53. PubMed ID: 18416942
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
